S&P 500   4,692.18 (+0.12%)
DOW   35,680.76 (-0.11%)
QQQ   398.62 (+0.20%)
AAPL   174.48 (+1.93%)
MSFT   332.54 (-0.71%)
FB   330.86 (+2.49%)
GOOGL   2,944.52 (-0.03%)
AMZN   3,524.78 (+0.04%)
TSLA   1,062.54 (+1.03%)
NVDA   320.37 (-1.20%)
BABA   125.87 (+0.26%)
NIO   34.97 (+5.59%)
CGC   11.07 (+4.04%)
AMD   145.01 (+0.11%)
GE   98.50 (+0.97%)
MU   85.94 (+0.13%)
T   23.18 (+0.43%)
F   19.86 (-0.50%)
DIS   153.43 (+1.74%)
PFE   51.50 (-0.43%)
AMC   33.04 (+6.44%)
ACB   6.67 (+4.55%)
BA   211.49 (+1.27%)
S&P 500   4,692.18 (+0.12%)
DOW   35,680.76 (-0.11%)
QQQ   398.62 (+0.20%)
AAPL   174.48 (+1.93%)
MSFT   332.54 (-0.71%)
FB   330.86 (+2.49%)
GOOGL   2,944.52 (-0.03%)
AMZN   3,524.78 (+0.04%)
TSLA   1,062.54 (+1.03%)
NVDA   320.37 (-1.20%)
BABA   125.87 (+0.26%)
NIO   34.97 (+5.59%)
CGC   11.07 (+4.04%)
AMD   145.01 (+0.11%)
GE   98.50 (+0.97%)
MU   85.94 (+0.13%)
T   23.18 (+0.43%)
F   19.86 (-0.50%)
DIS   153.43 (+1.74%)
PFE   51.50 (-0.43%)
AMC   33.04 (+6.44%)
ACB   6.67 (+4.55%)
BA   211.49 (+1.27%)
S&P 500   4,692.18 (+0.12%)
DOW   35,680.76 (-0.11%)
QQQ   398.62 (+0.20%)
AAPL   174.48 (+1.93%)
MSFT   332.54 (-0.71%)
FB   330.86 (+2.49%)
GOOGL   2,944.52 (-0.03%)
AMZN   3,524.78 (+0.04%)
TSLA   1,062.54 (+1.03%)
NVDA   320.37 (-1.20%)
BABA   125.87 (+0.26%)
NIO   34.97 (+5.59%)
CGC   11.07 (+4.04%)
AMD   145.01 (+0.11%)
GE   98.50 (+0.97%)
MU   85.94 (+0.13%)
T   23.18 (+0.43%)
F   19.86 (-0.50%)
DIS   153.43 (+1.74%)
PFE   51.50 (-0.43%)
AMC   33.04 (+6.44%)
ACB   6.67 (+4.55%)
BA   211.49 (+1.27%)
S&P 500   4,692.18 (+0.12%)
DOW   35,680.76 (-0.11%)
QQQ   398.62 (+0.20%)
AAPL   174.48 (+1.93%)
MSFT   332.54 (-0.71%)
FB   330.86 (+2.49%)
GOOGL   2,944.52 (-0.03%)
AMZN   3,524.78 (+0.04%)
TSLA   1,062.54 (+1.03%)
NVDA   320.37 (-1.20%)
BABA   125.87 (+0.26%)
NIO   34.97 (+5.59%)
CGC   11.07 (+4.04%)
AMD   145.01 (+0.11%)
GE   98.50 (+0.97%)
MU   85.94 (+0.13%)
T   23.18 (+0.43%)
F   19.86 (-0.50%)
DIS   153.43 (+1.74%)
PFE   51.50 (-0.43%)
AMC   33.04 (+6.44%)
ACB   6.67 (+4.55%)
BA   211.49 (+1.27%)

Pfizer Price Target, Predictions & Analyst Ratings

$51.50
-0.22 (-0.43 %)
(As of 12/8/2021 02:10 PM ET)
Add
Compare
Today's Range
$51.04
$53.06
50-Day Range
$41.32
$54.68
52-Week Range
$33.36
$55.70
Volume
1.28 million shs
Average Volume
31.78 million shs
Market Capitalization
$289.06 billion
P/E Ratio
15.33
Dividend Yield
3.03%
Beta
0.68

Pfizer (NYSE:PFE) Price Target and Consensus Rating

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analyst Rating Consensus

Hold
Based on 15 Analyst Ratings

Analyst Price Target Consensus

$50.53
-1.88% Downside

High PT$60.00
Average PT$50.53
Low PT$41.00
TypeCurrent
12/8/20 to 12/8/21
1 Month Ago
11/8/20 to 11/8/21
3 Months Ago
9/9/20 to 9/9/21
1 Year Ago
12/9/19 to 12/8/20
Consensus Rating
Hold
Hold
Hold
Hold
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
7 Buy rating(s)
4 Buy rating(s)
2 Buy rating(s)
5 Buy rating(s)
Hold
8 Hold rating(s)
9 Hold rating(s)
10 Hold rating(s)
9 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$50.53$45.46$43.08$40.14
Price Target Upside-1.88% Downside6.49% Upside6.74% Upside6.11% Upside
Get Pfizer Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for PFE and its competitors with MarketBeat's FREE daily newsletter.


Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

Average Share Price and Price Target by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Pfizer (NYSE:PFE) vs. Its Competitors

TypePfizerMedical CompaniesS&P 500
Consensus Rating Score
2.47
2.72
2.57
Consensus RatingHoldBuyBuy
Price Target Upside-1.88% Downside1,520.86% Upside9.99% Upside
News Sentiment RatingNeutral News
Neutral News
Neutral News
MarketBeat
Community Rating
Outperform Votes
1432
72.40%
Underperform Votes
546
27.60%
Avg. Outperform Votes
176
67.43%
Avg. Underperform Votes
85
32.57%
Avg. Outperform Votes
834
69.44%
Avg. Underperform Votes
367
30.56%

Pfizer (NYSE:PFE) Analyst Ratings History

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
11/29/2021JPMorgan Chase & Co.
Schott Chris
Boost Price TargetNeutral$42.00 ➝ $53.00-1.85%
11/29/2021Morgan Stanley
Matthew Harrison
Boost Price TargetSell ➝ Equal Weight$50.00 ➝ $60.00+11.11%
11/24/2021Truist Securities
Boost Price TargetBuy$43.00 ➝ $58.00+13.50%
11/18/2021BMO Capital Markets
Initiated CoverageOutperform$60.00+16.71%
11/17/2021Barclays
Gould Carter
Set Price Target$44.00-13.64%
11/11/2021Independent Research
Tobias Gottschalt
UpgradeBuy$53.00+5.51%
11/5/2021Cantor Fitzgerald
Louise Chen
Reiterated RatingBuy$60.00+23.43%
11/5/2021Benchmark
Boost Price TargetBuy$29.00 ➝ $45.00-7.29%
11/3/2021SVB Leerink
Lower Price TargetMarket Perform$50.00 ➝ $48.00+5.61%
10/3/2021Mizuho
Reiterated RatingHold$43.00+0.16%
7/29/2021The Goldman Sachs Group
Flynn Terence
Set Price Target$48.00+11.94%
7/29/2021Royal Bank of Canada
Set Price Target$44.00+1.27%
6/15/2021Berenberg Bank
Reiterated RatingNeutral$43.00+8.50%
2/3/2021DZ Bank
Reiterated RatingHold ➝ Buy$41.00+17.11%
11/10/2020Sanford C. Bernstein
Initiated CoverageMarket Perform$42.00+7.14%
10/12/2020Atlantic Securities
DowngradeOverweight ➝ Neutral$44.00 ➝ $39.00+6.01%
7/29/2020UBS Group
Boost Price TargetNeutral$37.00 ➝ $39.00+0.96%
6/26/2020Piper Sandler
Boost Price Target$18.50 ➝ $24.00-24.25%
2/27/2020Standpoint Research
UpgradeHold ➝ Buy
11/6/2019Credit Suisse Group
Reiterated RatingHold$41.30+10.06%
10/16/2019Bank of America
Initiated CoverageNeutral$37.00+1.82%
2/20/2019Citigroup
Andrew Baum
Reiterated RatingSell ➝ Neutral$41.00-3.76%
1/31/2019Argus
UpgradeHold ➝ Buy$55.00+32.28%
(Data available from 12/8/2016 forward. View 10+ years of historical ratings with our analyst ratings screener.)












Pfizer (NYSE:PFE) Analyst Ratings Frequently Asked Questions

What is Pfizer's consensus rating and price target?

According to the issued ratings of 15 analysts in the last year, the consensus rating for Pfizer stock is Hold based on the current 8 hold ratings and 7 buy ratings for PFE. The average twelve-month price target for Pfizer is $50.53 with a high price target of $60.00 and a low price target of $41.00. Learn more on PFE's analyst rating history

Do Wall Street analysts like Pfizer more than its competitors?

Analysts like Pfizer stock less than the stock of other Medical companies. The consensus rating for Pfizer is Hold while the average consensus rating for medical companies is Buy. Learn more on how PFE compares to other companies

Do MarketBeat users like Pfizer more than its competitors?

MarketBeat users like Pfizer stock more than the stock of other Medical companies. 72.40% of MarketBeat users gave Pfizer an outperform vote while medical companies recieve an average of 67.43% outperform votes by MarketBeat users.

Is Pfizer being upgraded by Wall Street analysts?

Over the previous 90 days, Pfizer's stock had 1 upgrade by analysts.

Does Pfizer's stock price have much upside?

According to analysts, Pfizer's stock has a predicted upside of 8.24% based on their 12-month price targets.

What analysts cover Pfizer?

This page was last updated on 12/8/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.